Introduction {#Sec1}
============

α-Synucleinopathies are neurodegenerative diseases characterized by the abnormal accumulation of *α*-synuclein (*α*-Syn) aggregates in neurons and glial cells. They include Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). The classification of these disorders is based on the clinical presentation, cellular location, and spatio-temporal development of aberrant *α*-Syn pathology, but they are clinically and pathologically overlapping disorders. In PD and DLB, *α*-Syn aggregates are in the neuronal cytoplasm and axonal processes into Lewy bodies and Lewy neurites, respectively, whereas α-Syn inclusions in oligodendroglia are the recognized neuropathologic hallmarks of MSA \[[@CR1]\]. Differentiation between PD, DLB and MSA continues to be a problematic diagnostic dilemma \[[@CR2]\]. At this end, here, we will describe three patients with a similar profile of initial symptomatology but who received a different clinical diagnosis by specialists in movement disorders according to the current diagnostic criteria. We will highlight a major degree of overlap between these conditions, especially focusing on the insidious and early coexistence of autonomic and cognitive dysfunction in the setting of overt or latent parkinsonism as pitfalls in the differential diagnosis of parkinsonian syndromes.

Case 1 presentation {#Sec2}
-------------------

A 65-year-old left-handed male presented to a first neurological visit after a transient loss of consciousness. He had previously been seen by cardiologist who had excluded cardiovascular disorders. The patient's past medical history included only a recent diagnosis of benign prostatic hypertrophy and he was taking no medications. The patient's syncope occurred upon standing and a history of recurring, short-lasting symptoms upon postural challenge, including light-headedness or visual disturbances, that began 2 years ago, was noted. Moreover, the neurological exam provided additional clues, revealing parkinsonian features, so that the patient was referred to our movement disorder clinic. At time of consultation, he described balance impairments associated with slow gait and reduced dexterity in fine motor skills with the right hand for the last year. At examination, there was clear evidence of mild bilateral parkinsonism with a prevalence of rigidity and bradykinesia in the right arm and right leg. Cerebellar and pyramidal tract signs were absent. Mild postural instability was noted. He was well oriented and reported no difficulties performing his work, but he complained a 2-year history of subjective memory disturbances involving mainly perceived difficulties with concentration and episodic memory, that do not disrupt daily activities. A detailed neuropsychological evaluation showed executive dysfunction, mild deficits in verbal memory and difficulties in the clock-drawing test consistent with a multidomain cognitive impairment. Additionally, he reported several nonmotor features suggestive of α-synucleinopathies, rapid eye movement (REM) sleep behavior disorder (RBD), constipation, and urinary urgency. Brain magnetic resonance imaging (MRI) was normal. Orthostatic change in blood pressure (BP) was measured finding an orthostatic fall in systolic BP of 20 mmHg and in diastolic BP of 10 mmHg. Autonomic function testing confirmed the hypotensive response on tilt-table testing and a lack of vasoconstriction during Valsalva maneuver. Dopamine transporter imaging single photon emission computed tomography (DAT-SPECT) was consistent with neurodegenerative parkinsonism. As a result of mild parkinsonism and prevailing autonomic symptoms, levodopa therapy was initially postponed.

A diagnosis of possible MSA-parkinsonian subtype (MSA-P) was made.

Yet, the severity and distribution of nonmotor symptoms was relatively stable over the next 2 years. Of note, global cognition scores declined slightly over the first 6 years. Initiation of levodopa was associated with improvement in motor symptoms and motor complications (both fluctuations and dyskinesias) emerged after 4 years of levodopa therapy. ^\[[@CR122]\]^I-metaiodobenzylguanidine (^\[123\]^I-MIBG) scintigraphy, performed 2 years after the onset of the symptoms, showed reduced cardiac sympathetic innervation. The patient's condition deteriorated after 7 years because of increasing confusion, disturbed sleep, and visual hallucinations, reflecting the progression of cognitive dysfunction to frank dementia. Freezing of gait and postural instability became a substantial cause of motor disability after 8 years from the diagnosis. Death ensued after 2 years at a nursing home.

*Could we refine the diagnosis from MSA-P to PD?*

Case 2 presentation {#Sec3}
-------------------

A 67-year-old right-handed male was seen at the memory clinic because he reported a 2-year history of subjective cognitive impairment, without effects on daily functioning. His history was significant for hypertension and dyslipidemia. Brain MRI was normal. Mini-Mental State Examination (MMSE) was reported as normal, but cognitive testing showed prominent deficits on executive function tests, verbal fluency, and visual recognition memory test. He received an initial diagnosis of non-amnestic mild cognitive impairment (MCI). However, constipation, orthostatic dizziness, urge incontinence, and RBD were reported. Taken together, these findings could suggest the existence of Lewy body pathology and the case was discussed with a movement disorder specialist. At examination, he presented a general impression of movement poverty and subtle motor signs, such as reduced left arm swing, mild stiffness, and slowed finger tapping in the left hand, were detected. Orthostatic intolerance was more prominent in the morning and it was likely resulted in sporadic syncopal episodes. Patient was evaluated for the presence of orthostatic hypotension (OH) and drop in systolic BP \> 30 mmHg within 3 min after adopting the standing position was observed. Head-up tilting and the blood pressure response to the Valsalva manoeuvre confirmed the autonomic failure as well as presynaptic dopaminergic imaging with SPECT-detected nigrostriatal degeneration. However, his most bothersome symptoms were memory disturbances and distractibility. An 18F-fluorodeoxyglucose positron emission tomography (^18F^FDG-PET) was characterized by a relative hypometabolism of the frontal and parieto-temporal cortices. When he started levodopa, a transient beneficial response was also reported.

Overall, the presence of all these features in MCI patients alerted us that this could be the early stage of DLB.

However, a second brain MRI was repeated after 2 years providing evidence of characteristic putaminal atrophy as well as the putaminal rim sign. Thereafter, he experienced a fast progression with the development of urinary incontinence and incomplete bladder emptying, postural instability, dementia and dysphagia within the next 5 years. The patient died 2 years later at the age of 74 years as a result of acute aspiration pneumonia.

*Should we refine the initial diagnosis from prodromal DLB to MSA-P?*

Case 3 presentation {#Sec5}
-------------------

A 74-year-old right-handed woman with a 7-month history of postural dizziness, sleep disturbances, and memory problems presented to the neurology clinic. Her family noted also changes in gait and slowness of movements. In the suspect of parkinsonism, the patient was referred to our movement disorder clinic. At time of consultation, she showed decreased mimicry and an asymmetrical (right \> left) akinetic-rigid syndrome with a shuffling gait. The Unified Parkinson\'s Disease Rating Scale (UPDRS) part III was 15. Her specific comorbidities included glaucoma and osteoporosis. She reported orthostatic intolerance, urinary incontinence, and constipation. RBD was documented on polysomnogram. MMSE was normal but cognition was assessed with a standardized test battery, showing mild deficits in executive function and letter fluency, without any impact on the patient's autonomy. There was significant autonomic dysfunction as demonstrated by BP readings in clinic and subsequent autonomic testing (with a sustained fall in systolic BP of \> 20 mmHg). Brain MRI was unremarkable. DAT-SPECT was consistent with bilateral reduced presynaptic nigrostriatal function. ^18F^FDG-PET did not identify hypometabolic areas. Improvement in motor symptoms was reported with low-dose levodopa therapy.

A diagnosis of probable PD was made.

However, during follow-up, cognitive disturbances progressed to dementia after 2 years, she increasingly showed hypo- and bradykinetic signs and she developed further nonmotor features (well-formed visual hallucinations and cognitive fluctuations), which increased the uncertainty of the PD diagnosis, resulting in the diagnostic dilemma between PD and DLB.

*Should we refine the initial diagnosis from PD to prodromal DLB?*

The Ethics Committee of our institution approved this article and all patients gave written informed consent.

Discussion {#Sec7}
==========

This study confirms that early differential diagnosis between α-synucleinopathies can be difficult, especially because they might initially present with overlapping clinical features \[[@CR3]\]. All *α*-synucleinopathies have in common autonomic nervous system dysfunctions, comprising OH, thermoregulatory, urogenital dysfunction, and gastrointestinal symptoms \[[@CR4]\]. Of note, symptoms of OH have been reported in 18--58% of PD patients, 30--50% of DLB patients, and 81% of MSA patients \[[@CR5]--[@CR7]\]. Also, cognitive impairment in PD is a highly common complication of late-stage disease \[[@CR8]\], heralds the onset of illness in advance of parkinsonian motor signs in DLB \[[@CR9]\] and is common in both MSA subtypes (the MSA-P and the cerebellar variant, MSA-C) \[[@CR10]\]. Importantly, autonomic dysfunction and cognitive impairment can be both present from the earliest phase of all α-synucleinopathies, independent of medication \[[@CR11]--[@CR14]\]. Additionally, there is now great interest in the idea that the nonmotor features of α-synucleinopathies may even precede diagnosis by several years, constituting 'prodromal' PD, DLB, and MSA \[[@CR15]--[@CR17]\].

This study reinforces the concept of clinical overlap between PD, DLB, and MSA-P, highlighting possible critical issues associated with current clinical criteria due to the increased recognition of dysautonomia and cognitive dysfunction as common nonmotor symptoms across different *α*-synucleinopathies (Fig. [1](#Fig1){ref-type="fig"}). Nonetheless, a critical distinction in clinical practice and research is important because the treatment and prognosis of patients with PD and those with atypical parkinsonian disorders differ. Moreover, this is also relevant to inform clinical studies on which subjects may be most suitable for inclusion in neuroprotective trials. We acknowledge that the diagnostic accuracy of clinical assessment should be evaluated using pathologic examination as gold standard so that the lack of neuropathological confirmation represents the main limitation of this work. However, diagnosis was clinically confirmed in our patients using strict published criteria and long-term clinical follow-up throughout their illness until death and was further supported by neuroimaging tools. Indeed, patients were reassessed by movement disorders neurologists every 6 months and treated in line with best clinical judgement.Fig. 1Graphical representation of possible overlaps of orthostatic hypotension and cognitive disturbances in dementia with Lewy bodies, Parkinson's disease and multiple system atrophy. Differential diagnosis, especially in early stages, can be difficult when orthostatic hypotension and cognitive impairment are both present but with mild severity

Current diagnostic criteria for α-synucleinopathies: where are we about dysautonomia and cognitive impairment? {#Sec8}
--------------------------------------------------------------------------------------------------------------

Currently, the diagnosis of PD relies on the recognition of the cardinal motor features and can be guided by the Movement Disorder Society (MDS) new clinical diagnostic criteria combining supportive and exclusionary clinical findings and clinical 'red flags' to assist the diagnosis (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR18]\]. 'Red flags' include "Severe autonomic failure in the first 5 years of disease as OH defined as orthostatic decrease of blood pressure within 3 min of standing by at least 30 mm Hg systolic or 15 mm Hg diastolic, in the absence of dehydration, medication, or other diseases that could plausibly explain autonomic dysfunction or severe urinary retention or urinary incontinence in the first 5 years of disease (excluding long-standing or small amount stress incontinence in women), that is not simply functional incontinence, and in men urinary retention not attributable to prostate disease, but associated with erectile dysfunction". On the other hand, in contrast with previous diagnostic criteria \[[@CR19]--[@CR21]\], the MDS-PD criteria do not consider dementia as an exclusion criterion for PD or as a 'red flag' suggestive of alternative diagnosis \[[@CR18]\].Fig. 2The different weight of orthostatic hypotension and cognitive impairment in DLB, MSA, and PD according to current diagnostic criteria (adapted from McKeith et al. \[[@CR9]\], Gilman et al. \[[@CR22]\], Postuma et al. \[[@CR18]\]). *DLB* dementia with Lewy bodies, *DSM-IV* Diagnostic and Statistic Manual of Mental Disorder, *PD* Parkinson's disease, *MDS* Movement Disorders Society, *MSA* multiple system atrophy, *REM* rapid eye movement

Diagnosis of MSA is based on consensus criteria that rely on either the presence of severe OH or urinary dysfunction indicating pathological involvement of autonomic neurons \[[@CR22]\], whereas cognitive impairment is not a typical presenting feature of patients with MSA. Of note, these guidelines emphasize the importance of autonomic failure, defined as "urinary incontinence (inability to control the release of urine from the bladder, with erectile dysfunction in males) or an orthostatic decrease of blood pressure within 3 min of standing by at least 30 mm Hg systolic or 15 mm Hg diastolic", for the diagnosis of probable or possible MSA (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR22]\].

DLB diagnostic criteria require the presence of specific core features such as fluctuating cognition, visual hallucinations, spontaneous parkinsonism, and RBD. OH and urinary incontinence are currently included as supportive features for clinical diagnosis (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR9]\]. However, in contrast to PD and MSA, OH is not otherwise specified. Additionally, other supportive clinical features for diagnosis of DLB such as repeated falls, syncope, and other transient episodes of unresponsiveness can also be partly attributable to the presence of autonomic dysfunction \[[@CR23]\].

Initial PD diagnosis is overall reconsidered in 10--30% of the patients during the follow-up and some "atypical" cases can be missed. Data from three different research groups report a diagnostic accuracy of only 58% for parkinsonian subjects with an initial, early diagnosis of PD \[[@CR24]--[@CR26]\] and the most common neuropathological findings in those with clinically diagnosed PD who did not have PD at autopsy have been either MSA or progressive supranuclear palsy (PSP) \[[@CR27]\]. The implementation of MDS-PD criteria have recently been reported to improve predictive value, such that over 95% of cases are accurately diagnosed \[[@CR28]\]. However, diagnostic inaccuracy has also been reported using clinical biomarkers for PD \[[@CR29]\]. Indeed, PD is highly heterogeneous in terms of clinical presentation as well as rate of progression and risk of disease complications and many patients may not follow the classic progression with variable clinicopathologic phenotypes and natural history \[[@CR30]\]. Many different groupings or subtype classification systems have been proposed, according to predefined criteria \[e.g., young vs old age at onset or dominance of tremor vs bradykinesia/rigidity\] or through a data-driven approach like cluster analysis, in which the profile of the subtypes arise from the data with no a priori hypothesis \[[@CR31]\]. PD subtypes based on motor features are most commonly used, but specific clinical descriptions of nonmotor symptom-dominant phenotypes have been recently defined \[[@CR32]\] and most critical determinants of PD subtype and prognosis have been identified in the presence of MCI, RBD, and OH at baseline \[[@CR33]\]. The same authors performed a cluster analysis using a different set of variables from Parkinson\'s Progression Markers Initiative (PPMI) data and found that these nonmotor features were the three key clustering variables to identify a 'diffuse malignant' clinical subtype in a minority of people with PD (10--25%) in which a broad range of key nonmotor symptoms is associated with prominent motor disability at early stages and faster progression, suggesting a severe and simultaneous involvement of dopaminergic and non-dopaminergic pathways at baseline \[[@CR34]\]. A recent review reinforced the association of OH and RBD with a malignant phenotype of PD characterized by early cognitive deficits, postural instability and reduced survival rate \[[@CR35]\]. Furthermore, there is clear evidence that PD patients have autonomic symptoms and subtle changes in cognition years before the diagnosis of disease \[[@CR15]\]. However, early and profound autonomic dysfunction is considered a 'red flag' against PD in MDS diagnostic criteria as well as there is much debate regarding the nosological classification of combined dementia and parkinsonism at disease onset \[[@CR18]\].

Autonomic failure represents the most frequent reason for misdiagnosing PD or DLB as MSA. A recent clinicopathological study has revealed that, of 134 patients clinically diagnosed with MSA meeting the diagnostic criteria for probable or possible MSA, only 83 (62%) had pathologically confirmed MSA and DLB was the pathologic diagnosis in 19 patients (37%) \[[@CR36]\]. An even larger study of 203 patients with an ante-mortem diagnosis of MSA showed that only 79% had pathologically confirmed MSA and misdiagnosed patients mainly had Lewy body disease or PSP pathology \[[@CR37]\]. As a result, a detailed critique of the second consensus criteria for MSA was recently published \[[@CR10]\], and a third revision was initiated in 2018 under the auspices of the International Parkinson and Movement Disorder Society (Fig. [2](#Fig2){ref-type="fig"}).

Similarly, the diagnosis of DLB may be challenging especially early in the course, as the clinical presentation is extremely variable among individual patients. A recent meta-analysis of the diagnostic accuracy of the clinical criteria found that about 20% of DLB diagnoses were incorrect and PD justified a relevant percentage of misdiagnosis (up to 10.8%) \[[@CR38]\]. New revised DLB consensus criteria have been recently updated for a more accurate and early diagnosis \[[@CR9]\].

Dysautonomia across α-synucleinopathies {#Sec9}
---------------------------------------

Among parkinsonian patients in whom OH is an early or dominant finding, the alternative diagnosis of MSA is usually favored \[[@CR39]\]. However, dysautonomia is not specific to MSA and does not develop simultaneously with motor symptoms in many MSA patients, contributing to delay a correct diagnosis \[[@CR40]\]. Furthermore, MSA does not start with autonomic failure in all patients and, depending on the study setting, rates of autonomic failure of up to 50% are reported at MSA disease onset \[[@CR41]\]. While it is true that autonomic involvement tends to be more severe and widespread and to have a more rapid progression in MSA compared with patients who have PD \[[@CR42]\], there are no clear-cut clinical criteria allowing physicians to discard MSA from idiopathic PD and the assessment of OH by formal laboratory testing has been found insufficient for differentiating among MSA and PD \[[@CR43]\]. Moreover, autonomic symptoms are not always easily quantified and only some of these tests can be performed easily in routine clinical practice \[[@CR44]\]. The site of the lesion might distinguish MSA from PD and, classically, it is believed that autonomic dysfunction is a result of preganglionic dysfunction in MSA and postganglionic part of the autonomic nervous system in PD \[[@CR45]\]. Of note, in contrast to PD, MSA patients show a greater involvement of the central autonomic network, primarily related to degeneration of preganglionic neurons of the brainstem and spinal cord, a more severe impairment of baroreflex activity and a relative preservation of plasma norepinephrine concentrations, consistent with the presence of intact noradrenergic nerve terminals \[[@CR46]\]. Accordingly, scintigraphy with ^\[[@CR122]\]^I-MIBG has been proposed for quantification of postganglionic sympathetic cardiac innervation and differential diagnosis of PD from MSA. However, recent evidence has challenged this view because ^\[[@CR122]\]^I-MIBG uptake results to be decreased in up to one-third of MSA patients, independent of disease duration and severity \[[@CR47]\]. Furthermore, recent studies have emphasized that its diagnostic performance is limited in the early stages of PD \[[@CR48]\] and patients with PD with autonomic failure can be indistinguishable from those with MSA in OH \[[@CR49]\]. It has been shown that up to 60% of PD patients with OH had already suffered from the symptom in the early phase of PD, even though most of these patients can be asymptomatic \[[@CR50], [@CR51]\] and even in some postmortem studies, early OH was recorded in autopsy-proven PD patients misdiagnosed as MSA \[[@CR52], [@CR53]\]. Conversely, one-third of patients with pathologically proven MSA die misdiagnosed with PD \[[@CR54]\]. It is worth to mention that brain MRI could aid in the differential diagnosis of parkinsonian syndromes and should be included in the initial evaluation of every patient with suspected atypical parkinsonism since specific MR abnormalities were reported to have high specificity for the diagnosis of MSA \[[@CR55]\]. Unfortunately, the sensitivity of MR atrophy patterns is low, especially in early disease stages, and it is correlated with the magnetic field strength. Furthermore, relatively few studies have evaluated the role of MRI in the early diagnosis of MSA \[[@CR56]\]. Similarly, a severe bilateral hypometabolism in the striatum, frontal cortex, cerebellum, and brainstem can be considered a specific pattern of glucose metabolism in MSA \[[@CR57]\]. However, ^18F^FDG-PET is not available everywhere and its sensitivity is variable. In contrast, substantia nigra hyperechogenicity in transcranial sonography (TCS) has proven useful for PD diagnosis offering good diagnostic reliability at a low cost beyond the research setting. However, conflicting data exist regarding the capacity of TCS to distinguish atypical parkinsonisms from PD, a missing temporal bone window is present in 10--20% of subjects, and it is heavily dependent on the investigator\'s experience and technical skills \[[@CR58]\]. Additionally, supine resting plasma norepinephrine levels seem able to predict whether the DLB/PD or MSA will eventually develop in patients with a diagnosis of pure autonomic failure (PAF), tending to be lower in PAF patients who phenoconverted to PD/DLB and higher in those that phenoconverted to probable MSA \[[@CR59]\].

Overall, these ancillary tests may help confirm a probable or possible MSA, but the clinical history and the neurological exam remain the key elements in formulating the diagnosis. In this context, distinguishing PD with OH from MSA-P can be very difficult clinically. Nonetheless, multiple autopsy studies have demonstrated that the lower brainstem, olfactory bulb, and autonomic nervous system are the areas affected earliest in the course of PD (Braak stage 1) \[[@CR60], [@CR61]\]. Earlier development of autonomic abnormalities is associated with postural instability and gait difficulty PD motor (PIGD) subtype, poorer levodopa treatment response and represents an independent determinant of more rapid disease progression and shorter survival in patients with PD \[[@CR62], [@CR63]\]. Furthermore, dysautonomia, especially baseline orthostatic blood pressure drop, is increasingly reported as a risk factor for development of dementia and is conceivable that OH may underlie fluctuations in PD dementia \[[@CR64]\].

Likewise, autonomic symptoms seem to be particularly prevalent in DLB and their prevalence is most likely underestimated because patients have cognitive impairment that could impede their ability to report the presence of autonomic disturbances. Severity and distribution of autonomic failure in DLB fall intermediately between PD and MSA, even though the most common autonomic symptom appears to be orthostatic intolerance \[[@CR65]\] and OH was the only symptom associated with shorter survival in 30 patients with DLB and Parkinson's disease dementia (PDD) \[[@CR66]\]. Autonomic features generally become evident later in the course of DLB, but they can be also common in the early stages and a presentation with prominent or isolated dysautonomia combined with parkinsonism in the absence of dementia has been reported, underscoring the broad clinical spectrum within which DLB may present \[[@CR12], [@CR67], [@CR68]\]. Postuma et al. \[[@CR69]\] demonstrated that patients who develop PD and DLB from idiopathic RBD have clear abnormalities of autonomic function years before the diagnosis of disease. In a case series of 90 patients with DLB, more than half displayed dysautonomic symptoms (particularly OH) prior to the onset of cognitive impairment \[[@CR70]\]. In agreement with such findings, functional imaging studies show that early on in DLB, as well in PD, amine uptake in postganglionic sympathetic neurons to the heart is already impaired \[[@CR71]\].

Cognitive dysfunction across α-synucleinopathies {#Sec10}
------------------------------------------------

The time of onset of dementia and less severe cognitive deficits in PD is highly variable but the majority of patients will develop dementia if they survive for more than 10 years after diagnosis with a cumulative incidence approaching 80% in some community studies \[[@CR72]\]. However, newly diagnosed idiopathic PD patients can have measurable cognitive decline at an early stage of disease \[[@CR13], [@CR73]\], highlighting cognitive impairment as a key feature from the time of diagnosis of PD and that the ascending pattern of α-syn deposits probably does not apply to all the clinical phenotypes of PD \[[@CR74]\]. Several previous studies of patients with untreated PD have shown frequencies of PD-MCI between 14.8 and 42.5% with early PD patients who exhibit impaired performance on a wide range of standardized neuropsychological tests \[[@CR75]--[@CR77]\]. Furthermore, early cognitive deficits are associated with worse motor and non‐motor features and have high prognostic value for predicting dementia in patients with PD \[[@CR78]\]. In particular, a worse performance in neuropsychological tasks that involve more posterior cortical function is considered a more robust predictor for global cognitive decline in patients with PD \[[@CR79]\]. In light of these evidences, the MDS task force, commissioned to consider a redefinition of PD, suggested that the presence of dementia should no longer be exclusionary for the diagnosis of PD and to abolish the '1‐year rule' separating PD and DLB \[[@CR80]\]. Notwithstanding, this has been a source of controversy \[[@CR81]\], and it is still not clear whether DLB and PDD are distinct disorders or the same disease at different stages. Indeed, both entities are closely related to notable overlap in their clinical presentation, pathological features, biochemistry, and genetic risk factors \[[@CR82]\]. Of note, most studies have not found reliable differences in neuropsychological function between PDD and DLB, with prominent executive dysfunction and visual-spatial abnormalities and variable impairment in memory capacities \[[@CR83], [@CR84]\]. Thus, the temporal sequence of dementia versus motor signs, which is the current distinguishing feature between the two disorders, may not be considered the optimal method for a diagnostic distinction in clinical practice, and many as half of all patients with DLB are also misdiagnosed with another type of dementia \[[@CR85]\].

Moreover, the identification of a DLB prodrome may result in a reduced confidence in differentiating DLB from PD \[[@CR17]\]. It is acknowledged that DLB can be preceded by amnestic or nonamnestic cognitive impairment, with nonamnestic MCI patients at a substantially higher risk of developing DLB than clinically probable Alzheimer's disease (AD) \[[@CR86]\]. Therefore, prodromal phase of DLB potentially identifies the non-demented individuals with DLB pathophysiological processes, whose cognitive deficits do not interfere with their capacity for independence in everyday activities. Research criteria for the diagnosis of MCI-DLB have now been published, and they wait for validation for use in clinical practice \[[@CR87]\]. Additionally, other core and suggestive features of DLB, such as fluctuating cognition, RBD and primary autonomic dysfunction, may emerge before patients develop a fully manifest DLB suggesting that prodromal DLB may exhibit different patterns of symptom onset and presentation \[[@CR87]--[@CR89]\]. Indeed, prodromal signs and symptoms of parkinsonism may be also present in prodromal DLB and are generally described as mild, precluding a diagnosis of PD but resulting indistinguishable from the subtle motor dysfunction of prodromal PD \[[@CR90]--[@CR92]\]. Moreover, the study of cognition in PD has shifted to increasingly early or initial cognitive decline and poor cognitive functioning has been associated with an increased risk of parkinsonism in participants of the Rotterdam Study, even after restricting the analysis to patients with incident parkinsonism without dementia, suggesting that cognitive dysfunction can be considered a sign of prodromal PD \[[@CR93]\]. Thus, the distinction between DLB and PD with cognitive impairment is unlikely to be useful or practicable at this stage and a general classification of 'prodromal LB disease' seems to be more appropriate \[[@CR94]\]. This potential overlap has been demonstrated also in patients with pure autonomic failure (PAF), an α-synucleinopathy of the peripheral autonomic nervous system. Indeed, PAF poses a similar prognostic dilemma, because after a period of time some patients may variably convert to a central nervous system synucleinopathy (PD, DLB or MSA) \[[@CR59]\].

Further, MSA cases present often with atypical features deviating from the classic well-delineated clinical phenotypes of MSA-P and MSA-C so that the clinical spectrum of MSA has expanded over recent years \[[@CR41]\]. For example, a 30--70% of patients with MSA may show an initial good therapeutic response to levodopa \[[@CR95]\], some patients may present with asymmetric parkinsonism \[[@CR96]\] and others may develop motor complications, including motor fluctuations and levodopa-induced dyskinesias \[[@CR97]\]. Moreover, a slow progression of parkinsonism resembling PD have occasionally been reported \[[@CR98]\], especially in the MSA-P type and in early-onset MSA patients \[[@CR99]\]. Further complicating matters, classically nonsupporting features of MSA that could be helpful in differentiating MSA from PD/DLB, may develop in patients with MSA: visual hallucinations have been reported to occur in 5--9% of patients with MSA \[[@CR100]\] whereas fluctuating cognition has never been systemically studied to date in MSA \[[@CR101]\]. Importantly, neuropsychiatric symptoms such as depression/apathy and anxiety commonly occur in MSA, ranging from 46 to 80% and 37 to 54%, respectively, and are reported to be more severe and prevalent in MSA-P patients \[[@CR102]\]. Similarly, although dementia was considered a nonsupportive criterion in the diagnosis of MSA according to the second consensus statement \[[@CR22]\], increasing evidence suggests that cognitive impairments are an integral part of the disease \[[@CR101]\] and dementia can occur with estimates reported in the range of 22--37% in autopsy-confirmed MSA patients \[[@CR103]\], whereas some cognitive impairment can be present in up to 75% of MSA patients \[[@CR104]\]. Several studies reported that patients with MSA exhibit more severe cognitive impairment, compared with that of severity- and age-matched patients with PD \[[@CR105], [@CR106]\]. Intriguingly, in a comparative study of cognitive impairment in DLB, MSA, and PD, the MSA group consistently performed in an intermediate level between the PD and DLB group \[[@CR2]\]. The interval from MSA diagnosis to clinically significant cognitive symptoms is estimated to be 7 years on average \[[@CR107]\]. However, the presence of cognitive decline among MSA patients who undergo neuropsychological assessment has been also reported at disease onset and, in some patients, the cognitive impairment has preceded motor impairment \[[@CR108]\]. Studies on cognitive function in MSA not only disclosed a broad spectrum of deficits in cognition and behavior describing frequently a profile that can be similar to that seen in PD and DLB, with predominant deficits in processing speed, verbal memory, and executive function \[[@CR109], [@CR110]\], but visuospatial and constructional dysfunction have also been reported \[[@CR111]\]. Similar to PD, MMSE does not seem sufficient to assess cognition in these patients \[[@CR112]\] and MoCA seems to be more sensitive to detect the mild cognitive decline in MSA \[[@CR113]\]. The cognitive dysfunction in patients with MSA-P showed a tendency to be more severe and widespread than that of patients with MSA-C, albeit relatively few detailed neuropsychological evaluations have been made in the MSA-C subgroup and few studies have addressed the possible differences between patients with predominant cerebellar or parkinsonian presentation \[[@CR114], [@CR115]\]. Attentive-executive functions are most likely declined in MSA which suggests a predominant frontal--subcortical pattern of cognitive dysfunction. Imaging studies and neuropathological findings support the idea that the cognitive decline in MSA originates predominantly from the frontal lobe involvement but recent data suggest that MSA and PD cognitive manifestations are associated with distinct underling mechanisms, indicating only a marginal contribution of cortical pathology but more impact of focal fronto-striatal degeneration \[[@CR109], [@CR116]\]. Parallel lines of evidence also indicate that the cerebellum is a potential region of interest for understanding cognitive deficits in both MSA-P and MSA-C subtypes \[[@CR117]\]. However, the heterogeneous nature of this pathology has been confirmed in autopsy-confirmed MSA cases that presented a clinical disease type of frontotemporal dementia \[[@CR118]\]. Intriguingly, published results show that patients with MSA and dementia had significantly reduced ^\[[@CR122]\]^I-MIBG cardiac uptake compared with the patients without dementia hampering further the diagnosis and differential diagnosis of MSA \[[@CR108]\]. Cardiovascular dysautonomia emerged as an independent predictor of cognitive impairment in MSA \[[@CR119]\].

Overall, there is increasing evidence of a striking relationship between dysautonomia and cognitive problems in neurodegenerative diseases, notably in α-synucleinopathies \[[@CR120], [@CR121]\], and several pathological mechanisms, not mutually exclusive, have been proposed to explain their association \[[@CR122]\]. OH is a common symptom in demented patients, including patients with AD and frontotemporal dementia \[[@CR123]\] and is associated with an increase in long-term risk of dementia \[[@CR124]\]. Despite the prevalence of dysautonomia in DLB, no association with cognitive impairment has been reported. In contrast, in early PD, cognitive impairment has been clearly associated with neurocirculatory abnormalities, especially OH \[[@CR125]\]. However, the literature addressing the relationship between cardiovascular autonomic failure and cognitive symptoms in PD has provided contradictory results \[[@CR126]--[@CR129]\] and it remains unclear whether such link is causative or associative. OH and cognitive impairment could be simply markers of a shared pathologic substrate in α-synucleinopathies and disease progression alone may account for this observed association, even though this is unlikely in early stages of disease. Of note, the two entities could be related because the same degenerating brain regions, such as the anterior cingulate cortex, control both cognitive and cardiovascular autonomic processes \[[@CR130]\]. Additionally, there is considerable support that transient decrements in cognition following postural change in PD patients are independently related to a failure of cerebral autoregulation during orthostatic stress \[[@CR131], [@CR132]\]. Finally, the association between OH and cognitive decline might reflect a common widespread peripheral and central noradrenergic loss \[[@CR133]\].

Conclusion {#Sec11}
==========

Whatever the explanation, clinicians should consider incorporating both autonomic and functional cognitive assessments in all persons with α-synucleinopathies regardless of subjective concerns brought forth by the patient. Early diagnosis of PD, DLB and MSA can still be challenging based exclusively on clinical findings because patients can show isolated or predominant cognitive disturbances and autonomic symptoms. This group may be misdiagnosed and overlooked if only predetermined criteria based on parkinsonism and dementia are used. In α-synucleinopathies, there are several possible clinical starting points and trajectories with a common final pathological and clinical syndrome, likewise a similar clinical pattern at disease onset may evolve over time into either PD, DLB, or MSA. Several observations challenge the weighting of early dysautonomia and cognitive dysfunction in DLB, PD, and MSA, highlighting critical issues associated with current diagnostic criteria. The combination of multimodal markers, including functional and molecular imaging, as well as cerebrospinal fluid and plasma biomarkers, will be helpful for both establishing early diagnostic criteria and for clinically definitive categorization of α-synucleinopathies in our continuing efforts to identify individuals at the earliest stages of the disease who would benefit from early symptomatic treatment and for inclusion in future trials.
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